Completed

Intra-arterial Chemotherapy for the Treatment of Progressive Diffuse Intrinsic Pontine Gliomas (DIPG).

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
What is being tested

Melphalan hydrochloride

Drug
Who is being recruted

Brain Diseases+15

+ Brain Neoplasms

+ Central Nervous System Diseases

From 1 Months to 17 Years
See all eligibility criteria
How is the trial designed

Other Study

Phase 1
Interventional
Study Start: March 2013
See protocol details

Summary

Principal SponsorSidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Last updated: March 28, 2019
Sourced from a government-validated database.Claim as a partner

Study start date: March 8, 2013

Actual date on which the first participant was enrolled.

Delivering the chemotherapeutic agent directly to the tumor via the arterial system avoids the complications and adverse events associated with toxicity from systemic chemotherapy.

NCT01688401
Principal SponsorSidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Last updated: March 28, 2019
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.
Design Details

3 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Other Study

Some studies explore topics that don't fall into a specific category. These might include innovative research, new technologies, or emerging healthcare areas.



Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Any sex

Biological sex of participants that are eligible to enroll.

From 1 Months to 17 Years

Range of ages for which participants are eligible to join.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

Brain DiseasesBrain NeoplasmsCentral Nervous System DiseasesGliomaNeoplasmsNeoplasms by Histologic TypeNeoplasms by SiteNeoplasms, Germ Cell and EmbryonalNeoplasms, Glandular and EpithelialNeoplasms, Nerve TissueNervous System DiseasesNervous System NeoplasmsInfratentorial NeoplasmsCentral Nervous System NeoplasmsNeuroectodermal TumorsNeoplasms, NeuroepithelialBrain Stem NeoplasmsDiffuse Intrinsic Pontine Glioma

Criteria

Inclusion Criteria: Pediatric patients of all ages with progressive DIPG. Consensus following presentation of the case at the multidisciplinary Pediatric Neuro-Oncology conference, which includes participation of neuro-oncology, neurosurgery, radiation oncology, interventional neuroradiology and neurology. Exclusion Criteria: Documented hypercoagulable disorders or vasculopathies INR value more than a Grade 1 toxicity by CTCAE v 4.0 criteria (>1 - 1.5 x ULN; >1 - 1.5 times above baseline if on anticoagulation). APTT value more than a Grade 1 toxicity by CTCAE v 4.0 criteria (>ULN - 1.5 x ULN). Platelets less than 50 x 103/mm3 Absolute neutrophil count less than 500/ mm3 Pregnancy Documented severe allergic reaction to IV iodinated contrast, specifically bronchospasm and anaphylaxis.

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.
Treatment Groups
Study Objectives

One single intervention group is designated in this study

This study does not include a placebo group 

Treatment Groups

Group I

Experimental
IA melphalan is administered via the basilar artery.

Study Objectives

Primary Objectives

Secondary Objectives

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 1 location

The Johns Hopkins Hospital

Baltimore, United StatesOpen The Johns Hopkins Hospital in Google Maps
CompletedOne Study Center